ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease

By Boger R.H.   Zoccali C.  

Atherosclerosis, Supplements, Vol. 4, Iss. 4, 2003-12 ,pp. : 23-28

Elsevier

Access to resources Recommend Favorite

Relative importance of risk factors for coronary heart disease – The Hordaland Homocysteine Study

By Igland Jannicke   Vollset Stein Emil   Nygård Ottar Kjell   Gjessing Håkon Kristian   Ueland Per Magne   Tell Grethe S.  

Scandinavian Cardiovascular Journal, Vol. 46, Iss. 6, 2012-12 ,pp. : 316-323

Informa Healthcare

Access to resources Recommend Favorite

Risk Factors in Cardiovascular Disease in Systemic Lupus Erythematosus

By  

Current Cardiology Reviews, Vol. 9, Iss. 1, 2013-02 ,pp. : 15-19

Bentham Science Publishers

Access to resources Recommend Favorite

Plasma homocysteine and the genetics of cardiovascular disease

By Souto Juan Carlos   Soria José Manuel  

Future Cardiology, Vol. 2, Iss. 2, 2006-03 ,pp. : 169-178

Future Medicine

Access to resources Recommend Favorite

Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA

By Lentz S.R.   Rodionov R.N.   Dayal S.  

Atherosclerosis, Supplements, Vol. 4, Iss. 4, 2003-12 ,pp. : 61-65

Elsevier

Access to resources Recommend Favorite